国产精品区一 I 欧美xxxx做受视频 I 亚洲中文字幕人成乱码 I 小早川怜子xxxxaⅴ在线 I 亚洲一区欧美激情 I 黄色免费观看网址 I 91成人小视频 I 日韩在线视频观看 I 强迫大乳人妻中文字幕 I 桃花久久 I 久久天天躁夜夜躁狠狠躁 I 精品人妻伦一二三区久久aaa片 I 日韩亚洲欧美视频 I 欧美国产精品久久久 I 亚洲女人天堂 I 亚洲免费性 I 在线观看国产精品普通话对白精品 I av大秀 I 91av综合 I 两个人看的www视频免费完整版 I 51自拍视频 I 911亚洲精品第一 I 日本美女毛片 I 午夜亚洲福利在线老司机 I 亚洲精品成人av I 亚洲精品无码久久久久av麻豆 I 欧美一级片网站 I 特黄熟妇丰满人妻无码 I 黄色片xxx I 日本熟妇xxxx潮喷视频

Accelerating innovative R&D and ploughing deeply in anti-virus field!

On the evening of August 18, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that Shenzhen Kexing Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenzhen Kexing"), a wholly-owned subsidiary of Kexing Biopharm, had recently received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), indicating that its clinical trial application for "human interferon α1b inhalation solution" was accepted.

Main Contents of Notice of Acceptance
1. Product Name: Human Interferon α1b Inhalation Solution
2. Application Item: clinical trial for registration of drugs produced in China
3. Acceptance No.: CXSL2200382G, CXSL2200383G
4. Indication: respiratory syncytial virus-associated lower respiratory infections (pneumonia, bronchiolitis) in children
5. Dosage Form: inhalation preparation

The promotion of the R&D of Human Interferon α1b Inhalation solution will help the Company further optimize the portfolio of antiviral drugs, enrich the product pipelines, enhance the overall R&D capability, and build up the long-term profitability.

Interferon α1b inhalation solution

Interferon (IFN) is a family of protein with broad-spectrum antiviral, anti-tumor and immunomodulatory effects, acting as a key component in body's natural immunity. Interferon α1b inhalation solution represents another major breakthrough in the antiviral field achieved by the Company. It is designed specifically for children by using a nebulizer, which can directly deliver the active ingredients to the lesions, resulting in a faster therapeutic effect, so as to free the pediatric patients from pains caused by injections and improve the compliance.